Regeneron Pharmaceuticals, Inc. will target Evkeeza (evinacumab-dgnb) to an ultra-rare patient population with homozygous familial hypercholesterolemia (HoFH) and price it in the range that has become commonplace for drugs for ultra-rare conditions. The wholesale acquisition cost (WAC) in the US is based on weight but is expected to be approximately $450,000 per year on average, the firm said.
The US Food and Drug Administration approved Evkeeza for patients 12 and older with HoFH as an adjunct to other...
